Physician profile

Robert G Lang

Neurological Surgery · Olympia, WA

NPI 1427127455

$905.31

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$97.94

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $333.87 2021-2023
Microvention, INC. $141.15 2019
Allergan, INC. $139.51 2019-2020
Biohaven Pharmaceutical Holding Company Ltd. $66.58 2022
Nuvasive, INC. $54.59 2019
Pfizer INC. $39.90 2020
Biohaven Pharmaceuticals, INC. $32.96 2021
Lilly USA, LLC $29.23 2020-2021
Amgen INC. $24.91 2019
Biodelivery Sciences International, INC. $18.18 2021
Horizon Therapeutics Plc $13.38 2019
Fidia Pharma USA INC. $11.05 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert G Lang

$905.31

in general payments reported 2019-2025

Years
2019-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/1087151/robert-g-lang

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.